{"id":"rhifn-beta-1b","safety":{"commonSideEffects":[{"rate":"50-70%","effect":"Flu-like symptoms"},{"rate":"20-40%","effect":"Injection site reactions"},{"rate":"10-30%","effect":"Fatigue"},{"rate":"10-30%","effect":"Headache"},{"rate":"5-20%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Interferon beta-1b works by binding to the interferon beta receptor, which triggers a signaling cascade that reduces the production of pro-inflammatory cytokines and promotes the production of anti-inflammatory cytokines. This leads to a decrease in inflammation and a reduction in the severity of symptoms associated with multiple sclerosis.","oneSentence":"rhIFN beta-1b is a recombinant form of interferon beta-1b that modulates the immune system to reduce inflammation in the central nervous system.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:32:02.206Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing forms of multiple sclerosis"}]},"trialDetails":[{"nctId":"NCT01464905","phase":"PHASE3","title":"Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)","status":"UNKNOWN","sponsor":"Nuron Biotech Inc.","startDate":"2011-10","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":500}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"rhIFN beta-1b","genericName":"rhIFN beta-1b","companyName":"Nuron Biotech Inc.","companyId":"nuron-biotech-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"rhIFN beta-1b is used to treat Relapsing Remitting Multiple Sclerosis. It is a recombinant human interferon beta-1b, which is a type of protein that has been shown to have therapeutic effects in this condition.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}